Relapses do not matter in relation to long-term disability: Yes

Multiple Sclerosis Journal

Volumn 17, Issue 12, 2011, Pages 1412-1414

  Casserly, Courtney ^a   Ebers, George C ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; DISABILITY; HUMAN; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NEUROPATHOLOGY; NEUROPATHY; PHENOTYPE; RELAPSE; THERAPY EFFECT;

EID: 82555194254     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511427514     Document Type: Article

References (10)

1. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis: A geographically based study 10. Relapses and long-term disability. Brain. 2010 ; 133: 1914-1929
2. Charcot JM. Histology de la Sclerose en Plaque. Gaz Hop (Paris). 1868 ; 41: 554 557 566-555 558
3. DeLuca GC, Williams K, Evangelou N, Ebers GC, Esri MM. The contribution of demyelination to axonal loss in multiple sclerosis. Brain. 2006 ; 129: 1507-1516 (Pubitemid 43999383)
4. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci. 2008 ; 31: 247-269
5. Noseworthy JH, Vandervoort MK, Hopkins M, Ebers GC. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop. Neurology. 1989 ; 39: 977-981 (Pubitemid 19170426)
6. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical trial results from a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993 ; 43: 655-661
7. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Colombia MS/MRI Analysis Group. Neurology. 1995 ; 45: 1277-1285
8. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, et al. Monoclonal antibody treatment exposes the mechanism underlying the clinical course of multiple sclerosis. Ann Neurol. 1999 ; 46: 296-304 (Pubitemid 29416266)
9. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999 ; 122: 1941-1950
10. Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuck DM, Ebers GC. The natural history of multiple sclerosis: A geographically based study 9. Observations on the progressive phase of the disease. Brain. 2006 ; 129: 584-594 (Pubitemid 43278221)